JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

Search

Madrigal Pharmaceuticals Inc

Închisă

SectorSănătate

414.82 -2.95

Rezumat

Modificarea prețului

24h

Curent

Minim

412.15

Maxim

427.51

Indicatori cheie

By Trading Economics

Venit

31M

-42M

Vânzări

76M

213M

EPS

-1.9

Marjă de profit

-19.869

Angajați

528

EBITDA

31M

-39M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+17.77% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

2.9B

9.8B

Deschiderea anterioară

417.77

Închiderea anterioară

414.82

Sentimentul știrilor

By Acuity

50%

50%

168 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 oct. 2025, 22:47 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct. 2025, 22:13 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct. 2025, 21:20 UTC

Câștiguri

Correction to IBM 3Q Sales Jump Article

22 oct. 2025, 20:57 UTC

Câștiguri

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 oct. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct. 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct. 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct. 2025, 23:15 UTC

Câștiguri

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct. 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct. 2025, 22:02 UTC

Câștiguri

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct. 2025, 21:59 UTC

Achiziții, Fuziuni, Preluări

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct. 2025, 21:58 UTC

Achiziții, Fuziuni, Preluări

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct. 2025, 21:57 UTC

Achiziții, Fuziuni, Preluări

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct. 2025, 21:56 UTC

Achiziții, Fuziuni, Preluări

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct. 2025, 21:47 UTC

Achiziții, Fuziuni, Preluări

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct. 2025, 21:47 UTC

Câștiguri

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct. 2025, 21:47 UTC

Achiziții, Fuziuni, Preluări

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct. 2025, 21:46 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct. 2025, 21:28 UTC

Market Talk
Câștiguri

Correction to Alcoa Tariff Market Talk

22 oct. 2025, 21:25 UTC

Câștiguri

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct. 2025, 21:17 UTC

Câștiguri

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct. 2025, 21:09 UTC

Market Talk
Câștiguri

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22 oct. 2025, 20:59 UTC

Câștiguri

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct. 2025, 20:51 UTC

Câștiguri

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 oct. 2025, 20:44 UTC

Câștiguri

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparație

Modificare preț

Madrigal Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

17.77% sus

Prognoză pe 12 luni

Medie 506.43 USD  17.77%

Maxim 590 USD

Minim 266 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMadrigal Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

14

Cumpărare

1

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

263.2 / 277.1Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

168 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat